http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005026994-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate | 2001-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_286017dca927bbdc626895ace6ad37ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b9ca4884b083c7e6b1851b8af3833b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4db653b6ce394455258bc498bb29dfdf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e906dcafb877e2084f9e559745b75814 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbff3ba0ffabfa0d13484138e442241b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df21d21cae9bea29c8855c5819eaaed6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2762b97ff59fc48a0007e760b586a0fd |
| publicationDate | 2005-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005026994-A1 |
| titleOfInvention | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| abstract | The present invention relates to the new use of 2,4-diamino-3-hydroxycarboxylic acids of formula (I), in which A and B independently represent a bond or an unsubstituted or substituted amino acyl moiety; R 1 represents hydrogen; an amino protecting group; or a group of formula R 5 Y— wherein R 5 represents hydrogen or an unsubstituted or substituted alkyl, alkenyl, alkinyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl group; and Y represents —CO—; —NH—CO—; —NH—CS—; —SO 2 —; —O—CO—; or —O—CS—; R 2 represents the side chain of a natural amino acid; an alkyl, arylalkyl, heteroarylalkyl or cycloalkylalkyl group; or trimethylsilylmethyl, 2-thienylmethyl or styrylmethyl; R 3 represents halogen, alkyl, alkoxy or hydroxyalkoxy; and R 4 represents 2(R)-hydroxyindan-1(S)-yl; (S)-2-hydroxy-1-phenylethyl; or 2-hydroxy-benzyl unsubstituted or substituted in 4-position by methoxy; in the manufacture of a pharmaceutical composition for the treatment of a proliferative disease, e.g., of a solid tumor; to a method of treatment of warm-blooded animals; and to 2,4-diamino-3-hydroxycarboxylic acids of formula (I*), wherein A and B independently represent an unsubstituted or substituted amino acyl moiety; R 2 represents arylalkyl; R 3 represents halogen, alkyl, alkoxy or hydroxyalkoxy; R 4 represents 2-hydroxy-benzyl unsubstituted or substituted in 4 position by methoxy; and R 5 represents arylalkyl and Y represents —CO—; or R 5 represents alkyl substituted by cycloalkyl, naphthyl, pyridyl or phenyl in which phenyl is substituted by alkyl or amino; and Y represents —O—CO; pharmaceutically acceptable salts thereof; and the use of such compounds of formula (I*) for the therapeutic treatment of the human or animal body, especially the treatment of proliferative diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020040372-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010048583-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3009736-A2 |
| priorityDate | 1999-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 466.